Ummm... the numbers reported by pharma companies has nothing to do with the estimate DiMasi's group did. The pharma numbers are SEC approved financial statements. That real cash going to R&D, not some pie in the sky estimate.
But no idea how much of that is going into new or more effective versions of the drugs, how much to manufacturing process research, how much on sales research etc.